S. Blondel

Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in Patients With Hutchinson‐Gilford Progeria Syndrome

M. Peschanski, X. Nissan, N. Lévy, 2014, Stem cells translational medicine.

Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in PatientsWith Hutchinson-Gilford Progeria Syndrome

X. Navarro, M. Peschanski, X. Nissan, 2014 .

Cell-Based Drug Development , Screening , and Toxicology Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in PatientsWith Hutchinson-Gilford Progeria Syndrome

M. Peschanski, N. Lévy, C. Navarro, 2014 .

Unique preservation of neural cells in Hutchinson- Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA.

M. Peschanski, X. Nissan, N. Lévy, 2012, Cell reports.

In vitro pathological modelling using patient-specific induced pluripotent stem cells: the case of progeria.

M. Peschanski, X. Nissan, S. Blondel, 2011, Biochemical Society transactions.

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells

M. Peschanski, X. Nissan, N. Lévy, 2016, npj Aging and Mechanisms of Disease.

Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation

M. Peschanski, J. Tournois, X. Nissan, 2016, Cell Death and Disease.